JOSEPH M. KIELY, M.D., F.A.C.P.; DON C. PURNELL, M.D., F.A.C.P.; CHARLES A. OWEN JR., M.D.
This content is PDF only. Please click on the PDF icon to access.
Normochromic anemia of modest degree is common in myxedematous patients and may persist for months after institution of thyroid hormone therapy (1-3). The bone marrow tends to be hypocellular (4). Most investigators have found the red blood cell survival to be normal and generally suspect that the anemia is due to decreased erythropoiesis.
Iron deficiency anemia in women with myxedema is often due to menorrhagia and responds adequately to the administration of iron, without treatment of the hypothyroidism. Macrocytic anemia is usually due to the coexistence of pernicious anemia, which has a much higher prevalence in patients with myxedema than
KIELY JM, PURNELL DC, OWEN CA. Erythrokinetics in Myxedema. Ann Intern Med. ;67:533–538. doi: 10.7326/0003-4819-67-3-533
Download citation file:
Published: Ann Intern Med. 1967;67(3_Part_1):533-538.
Endocrine and Metabolism, Thyroid Disorders.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use